The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and
apoptosis by modulating
protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate
tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating
kinase enzymatic activity and accordingly modulating
kinase-dependent associated diseases and conditions such as cancers like
Thyroid carcinoma,
Ovarian carcinoma,
Pancreatic carcinoma, Prostatic
carcinoma,
Renal cell carcinoma,
Hepatocellular carcinoma,
Breast carcinoma, Colorectal
carcinoma, Oral squamous
cell carcinoma, Colorectal,
Lung adenocarcinoma or
Endometrial cancer.